• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks

    MedReleaf Obtains Good Manufacturing Practices Certification

    Written by Bryan Mc Govern
    |
    Jun. 19, 2017 08:30AM PST

    MedReleaf announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.

    MedReleaf (TSX:LEAF) announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.
    As quoted in the press release:

    MedReleaf’s wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility.
    Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada, the United States, EU, Japan, Singapore and Australia.
    MedReleaf’s ICH-GMP certification will support the Company’s international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, including:

    • Providing the Company with a global manufacturing practice and platform that complies with GMP requirements around the world.
    • Facilitating the sale of MedReleaf products to any global market allowing the import of medical cannabis.
    • Accelerating MedReleaf’s partnerships with pharmaceutical and biotech companies as the only ICH-GMP certified producer of medical cannabis that can be used in late-stage clinical trials around the world.

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical industryclinical trialsaustraliacanadapharmaceutical and biotech companies
    The Conversation (0)

    Go Deeper

    AI Powered
    Nextleaf Solutions

    Nextleaf Solutions

    Cannabis Weekly Round-Up: Cookies Brand Makes Leap to Europe

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES